Cargando…
Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses
Two primary causes of respiratory tract infections are respiratory syncytial virus (RSV) and influenza viruses, both of which remain major public health concerns. There are a limited number of antiviral drugs available for the treatment of RSV and influenza, each having limited effectiveness and eac...
Autores principales: | Pickens, Jennifer A., Tripp, Ralph A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795461/ https://www.ncbi.nlm.nih.gov/pubmed/29361733 http://dx.doi.org/10.3390/v10010048 |
Ejemplares similares
-
XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor
por: Pan, Lijia, et al.
Publicado: (2021) -
Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection
por: Perwitasari, Olivia, et al.
Publicado: (2016) -
Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication
por: Tripp, Ralph A., et al.
Publicado: (2022) -
Pathobiology of Respiratory Syncytial Virus (RSV)
por: Tripp, Ralph A., et al.
Publicado: (2020) -
Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice
por: Caidi, Hayat, et al.
Publicado: (2012)